Ngenla (Somatrogon)

Somatrogon, the active ingredient in Ngenla, is a growth hormone analog presented as a subcutaneous injection for subcutaneous use. It is indicated for the treatment of growth hormone deficiency in children, helping to support normal linear growth and metabolic development.

GNH USA supplies Ngenla as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved products to support pediatric endocrine care across global markets. Our distribution network ensures reliable delivery and cold‑chain handling where required.

Ngenla is a growth hormone analog used to address conditions caused by insufficient endogenous growth hormone. - Growth hormone deficiency in children: promotes linear growth and improves IGF‑1 levels. - Short stature due to GH deficiency: supports height gain during the growth period. - Metabolic effects of GH deficiency: helps normalize protein, lipid and carbohydrate metabolism.

Somatrogon may cause a range of adverse reactions, most of which are mild to moderate.

Common Side Effects: - Injection site reactions: redness, swelling or pain at the injection site. - Headache: mild to moderate intensity. - Abdominal discomfort: nausea or stomach pain. - Joint pain: arthralgia in limbs. - Peripheral edema: mild swelling of hands or feet. - Fatigue: feeling unusually tired.

Serious or Rare Side Effects: - Intracranial hypertension: symptoms include severe headache and visual changes. - Slipped epiphysis: risk of growth plate displacement. - Severe allergic reaction: rash, itching, swelling, or anaphylaxis. - Abnormal glucose metabolism: hyperglycemia or impaired tolerance. - Cardiomyopathy: rare heart muscle dysfunction. - Tumor progression: potential acceleration of existing malignancies.

Prior to initiating therapy, clinicians should evaluate patients for specific risk factors and monitor ongoing safety. - IGF‑1 monitoring: adjust dose to maintain target IGF‑1 range. - Intracranial hypertension: watch for persistent headaches or visual disturbances. - Glucose tolerance: assess fasting glucose and HbA1c periodically. - Skeletal health: screen for scoliosis or slipped epiphysis in rapidly growing children. - Hypersensitivity: discontinue if severe allergic reaction occurs. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Somatrogon may interact with other agents that affect growth hormone pathways or glucose metabolism.

Major Interactions (Avoid): - High‑dose glucocorticoids: may blunt the anabolic response. - Insulin or oral hypoglycemics: increased risk of hypoglycemia. - Oral estrogen therapy: can elevate IGF‑1 levels excessively.

Moderate Interactions (Monitor Closely): - Other growth hormone analogs: additive effects on IGF‑1. - Thyroid hormone replacement: may require dose adjustment. - Diuretics: can exacerbate peripheral edema.